Werewolf Historical Financial Ratios

HOWL Stock

USD 1.03 0.04 3.74%

Werewolf Therapeutics is currently reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.92 or Days Sales Outstanding of 26.99 will help investors to properly organize and evaluate Werewolf Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.

About Werewolf Financial Ratios Analysis

Werewolf TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Werewolf Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Werewolf financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Werewolf Therapeutics history.

Werewolf Therapeutics Financial Ratios Chart

At this time, Werewolf Therapeutics' EV To Operating Cash Flow is quite stable compared to the past year. EV To Free Cash Flow is expected to rise to 0.69 this year, although the value of Free Cash Flow Yield is projected to rise to (0.84).

Price To Sales Ratio Days Sales Outstanding Days Of Inventory On Hand Payables Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Werewolf Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Werewolf Therapeutics sales, a figure that is much harder to manipulate than other Werewolf Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from Werewolf Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Werewolf Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.At this time, Werewolf Therapeutics' EV To Operating Cash Flow is quite stable compared to the past year. EV To Free Cash Flow is expected to rise to 0.69 this year, although the value of Free Cash Flow Yield is projected to rise to (0.84).

	2024	2025 (projected)
Payables Turnover	26.21	27.52
Days Of Inventory On Hand	2.62E-4	2.33E-4

Payables Turnover Days Of Inventory On Hand

Werewolf Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets
Price To Sales Ratio		0.56	-0.82	0.25	-0.82	-0.56	-0.64	0.56	-0.94	-0.54	-0.51	-0.6	-0.95	0.81	-0.53	0.22	0.6	0.38	0.49	0.6	-0.66	-0.11	-0.81	0.59	0.62	-0.33
Ptb Ratio	0.56		-0.68	0.86	-0.78	-0.96	-0.98	1.0	-0.4	-0.96	0.34	-0.94	-0.5	0.69	-0.63	0.92	0.99	0.95	0.04	0.99	-0.44	-0.27	-0.93	1.0	0.99	0.49
Days Sales Outstanding	-0.82	-0.68		-0.4	0.71	0.55	0.76	-0.68	0.58	0.53	0.15	0.57	0.74	-1.0	0.92	-0.36	-0.71	-0.53	-0.45	-0.71	0.79	0.18	0.81	-0.69	-0.72	0.0
Book Value Per Share	0.25	0.86	-0.4		-0.58	-0.89	-0.74	0.86	-0.12	-0.9	0.37	-0.9	-0.21	0.41	-0.42	0.88	0.82	0.75	-0.12	0.82	-0.13	-0.59	-0.74	0.82	0.86	0.42
Free Cash Flow Yield	-0.82	-0.78	0.71	-0.58		0.8	0.78	-0.78	0.76	0.8	0.24	0.84	0.76	-0.71	0.49	-0.52	-0.83	-0.63	0.04	-0.83	0.72	0.39	0.93	-0.81	-0.85	0.05
Operating Cash Flow Per Share	-0.56	-0.96	0.55	-0.89	0.8		0.91	-0.96	0.48	1.0	-0.22	0.99	0.52	-0.56	0.43	-0.9	-0.95	-0.88	-0.01	-0.95	0.3	0.35	0.92	-0.95	-0.96	-0.37
Capex To Depreciation	-0.64	-0.98	0.76	-0.74	0.78	0.91		-0.98	0.46	0.9	-0.31	0.88	0.57	-0.77	0.69	-0.85	-0.98	-0.94	-0.15	-0.98	0.52	0.12	0.93	-0.98	-0.96	-0.48
Pb Ratio	0.56	1.0	-0.68	0.86	-0.78	-0.96	-0.98		-0.4	-0.96	0.34	-0.94	-0.5	0.69	-0.63	0.92	0.99	0.95	0.04	0.99	-0.44	-0.27	-0.93	1.0	0.99	0.49
Ev To Sales	-0.94	-0.4	0.58	-0.12	0.76	0.48	0.46	-0.4		0.45	0.65	0.51	0.9	-0.56	0.22	-0.1	-0.44	-0.23	-0.44	-0.44	0.47	0.08	0.68	-0.43	-0.46	0.47
Free Cash Flow Per Share	-0.54	-0.96	0.53	-0.9	0.8	1.0	0.9	-0.96	0.45		-0.24	0.99	0.5	-0.54	0.42	-0.91	-0.95	-0.88	0.04	-0.95	0.31	0.36	0.91	-0.95	-0.96	-0.38
Roic	-0.51	0.34	0.15	0.37	0.24	-0.22	-0.31	0.34	0.65	-0.24		-0.13	0.53	-0.12	-0.14	0.62	0.29	0.56	-0.31	0.29	0.24	0.19	0.03	0.32	0.23	0.97
Net Income Per Share	-0.6	-0.94	0.57	-0.9	0.84	0.99	0.88	-0.94	0.51	0.99	-0.13		0.56	-0.57	0.43	-0.85	-0.94	-0.82	0.01	-0.94	0.34	0.43	0.93	-0.93	-0.96	-0.27
Days Of Inventory On Hand	-0.95	-0.5	0.74	-0.21	0.76	0.52	0.57	-0.5	0.9	0.5	0.53	0.56		-0.72	0.43	-0.19	-0.54	-0.32	-0.46	-0.54	0.58	-0.02	0.74	-0.52	-0.55	0.35
Payables Turnover	0.81	0.69	-1.0	0.41	-0.71	-0.56	-0.77	0.69	-0.56	-0.54	-0.12	-0.57	-0.72		-0.93	0.37	0.71	0.54	0.41	0.71	-0.8	-0.19	-0.81	0.7	0.73	0.02
Capex To Revenue	-0.53	-0.63	0.92	-0.42	0.49	0.43	0.69	-0.63	0.22	0.42	-0.14	0.43	0.43	-0.93		-0.38	-0.63	-0.53	-0.32	-0.63	0.72	0.19	0.64	-0.62	-0.65	-0.23
Cash Per Share	0.22	0.92	-0.36	0.88	-0.52	-0.9	-0.85	0.92	-0.1	-0.91	0.62	-0.85	-0.19	0.37	-0.38		0.88	0.95	-0.11	0.88	-0.1	-0.18	-0.72	0.9	0.86	0.72
Pocfratio	0.6	0.99	-0.71	0.82	-0.83	-0.95	-0.98	0.99	-0.44	-0.95	0.29	-0.94	-0.54	0.71	-0.63	0.88		0.94	0.01	1.0	-0.51	-0.26	-0.94	1.0	0.99	0.45
Interest Coverage	0.38	0.95	-0.53	0.75	-0.63	-0.88	-0.94	0.95	-0.23	-0.88	0.56	-0.82	-0.32	0.54	-0.53	0.95	0.94		-0.07	0.94	-0.34	-0.05	-0.79	0.95	0.9	0.71
Capex To Operating Cash Flow	0.49	0.04	-0.45	-0.12	0.04	-0.01	-0.15	0.04	-0.44	0.04	-0.31	0.01	-0.46	0.41	-0.32	-0.11	0.01	-0.07		0.01	0.05	0.25	-0.18	0.01	0.02	-0.28
Pfcf Ratio	0.6	0.99	-0.71	0.82	-0.83	-0.95	-0.98	0.99	-0.44	-0.95	0.29	-0.94	-0.54	0.71	-0.63	0.88	1.0	0.94	0.01		-0.51	-0.26	-0.94	1.0	0.99	0.46
Days Payables Outstanding	-0.66	-0.44	0.79	-0.13	0.72	0.3	0.52	-0.44	0.47	0.31	0.24	0.34	0.58	-0.8	0.72	-0.1	-0.51	-0.34	0.05	-0.51		0.17	0.6	-0.5	-0.52	0.09
Income Quality	-0.11	-0.27	0.18	-0.59	0.39	0.35	0.12	-0.27	0.08	0.36	0.19	0.43	-0.02	-0.19	0.19	-0.18	-0.26	-0.05	0.25	-0.26	0.17		0.35	-0.24	-0.37	0.24
Roe	-0.81	-0.93	0.81	-0.74	0.93	0.92	0.93	-0.93	0.68	0.91	0.03	0.93	0.74	-0.81	0.64	-0.72	-0.94	-0.79	-0.18	-0.94	0.6	0.35		-0.93	-0.96	-0.14
Ev To Operating Cash Flow	0.59	1.0	-0.69	0.82	-0.81	-0.95	-0.98	1.0	-0.43	-0.95	0.32	-0.93	-0.52	0.7	-0.62	0.9	1.0	0.95	0.01	1.0	-0.5	-0.24	-0.93		0.99	0.48
Pe Ratio	0.62	0.99	-0.72	0.86	-0.85	-0.96	-0.96	0.99	-0.46	-0.96	0.23	-0.96	-0.55	0.73	-0.65	0.86	0.99	0.9	0.02	0.99	-0.52	-0.37	-0.96	0.99		0.38
Return On Tangible Assets	-0.33	0.49	0.0	0.42	0.05	-0.37	-0.48	0.49	0.47	-0.38	0.97	-0.27	0.35	0.02	-0.23	0.72	0.45	0.71	-0.28	0.46	0.09	0.24	-0.14	0.48	0.38

Click cells to compare fundamentals

Werewolf Therapeutics Account Relationship Matchups

Werewolf Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	(8.9)	2.13	0.48	1.24	0.87	0.92
Book Value Per Share	(1.81)	5.59	4.24	3.12	1.69	1.6
Free Cash Flow Yield	(0.0416)	(0.13)	(0.75)	(0.24)	(0.88)	(0.84)
Operating Cash Flow Per Share	(0.65)	(1.57)	(1.41)	(0.91)	(1.3)	(1.36)
Capex To Depreciation	3.73	2.31	3.27	0.44	0.14	0.13
Pb Ratio	(8.9)	2.13	0.48	1.24	0.87	0.92
Free Cash Flow Per Share	(0.67)	(1.59)	(1.53)	(0.94)	(1.3)	(1.37)
Roic	(0.24)	(0.29)	(0.38)	(0.25)	(0.65)	(0.68)
Net Income Per Share	(0.52)	(1.82)	(1.79)	(1.05)	(1.63)	(1.71)
Payables Turnover	0.76	0.36	2.06	29.12	26.21	27.52
Cash Per Share	3.23	5.77	4.48	3.77	2.59	2.73
Pocfratio	(24.78)	(7.59)	(1.46)	(4.22)	(1.14)	(1.2)
Capex To Operating Cash Flow	(0.0301)	(0.0116)	(0.0889)	(0.0236)	(0.004521)	(0.004747)
Pfcf Ratio	(24.06)	(7.5)	(1.34)	(4.12)	(1.14)	(1.19)
Days Payables Outstanding	479.62	1.0K	177.56	12.53	14.41	13.69
Income Quality	1.24	0.86	0.75	0.87	0.8	1.0
Roe	0.29	(0.33)	(0.42)	(0.34)	(0.96)	(0.91)
Ev To Operating Cash Flow	(19.95)	(4.28)	1.37	(1.69)	0.66	0.69
Pe Ratio	(30.89)	(6.54)	(1.15)	(3.68)	(0.91)	(0.95)
Return On Tangible Assets	(0.15)	(0.28)	(0.32)	(0.21)	(0.56)	(0.58)
Ev To Free Cash Flow	(19.36)	(4.23)	1.25	(1.65)	0.66	0.69
Earnings Yield	(0.0324)	(0.15)	(0.87)	(0.27)	(1.1)	(1.04)
Net Debt To E B I T D A	6.31	2.88	2.23	2.54	1.58	3.14
Current Ratio	17.58	13.56	5.84	7.14	7.45	11.08
Tangible Book Value Per Share	(1.81)	5.59	4.24	3.12	1.69	1.6
Shareholders Equity Per Share	(1.81)	5.59	4.24	3.12	1.69	1.6
Debt To Equity	(0.049)	0.1	0.12	0.47	0.15	0.088
Capex Per Share	0.0195	0.0182	0.13	0.0216	0.005862	0.005569
Graham Net Net	(1.94)	4.8	3.35	2.02	1.35	1.14
Interest Debt Per Share	0.0886	0.57	0.51	1.54	0.36	0.42
Debt To Assets	0.0264	0.0874	0.0916	0.3	0.0866	0.096
Enterprise Value Over E B I T D A	(26.04)	(3.72)	1.08	(1.7)	0.58	0.61
Price Earnings Ratio	(30.89)	(6.54)	(1.15)	(3.68)	(0.91)	(0.95)
Price Book Value Ratio	(8.9)	2.13	0.48	1.24	0.87	0.92
Days Of Payables Outstanding	479.62	1.0K	177.56	12.53	14.41	13.69
Price To Operating Cash Flows Ratio	(24.78)	(7.59)	(1.46)	(4.22)	(1.14)	(1.2)
Price To Free Cash Flows Ratio	(24.06)	(7.5)	(1.34)	(4.12)	(1.14)	(1.19)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports:

How To Invest In Werewolf

Details

Is Werewolf Stock a good investment?

Details

What is Werewolf Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.69)

Revenue Per Share

0.044

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.30)

Return On Equity

(0.76)

The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Werewolf Historical Financial Ratios

About Werewolf Financial Ratios Analysis

Werewolf Therapeutics Financial Ratios Chart

Price To Sales Ratio

Payables Turnover

Werewolf Therapeutics fundamentals Correlations

Werewolf Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Werewolf Therapeutics fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Ev To Operating Cash Flow	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Ev To Operating Cash Flow	+ 1.0	Pb Ratio
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio

Payables Turnover	- 1.0	Days Sales Outstanding
Ev To Operating Cash Flow	- 0.98	Capex To Depreciation
Pfcf Ratio	- 0.98	Capex To Depreciation
Pocfratio	- 0.98	Capex To Depreciation
Pb Ratio	- 0.98	Capex To Depreciation
Capex To Depreciation	- 0.98	Ptb Ratio